Optimizing the Procedure to Manufacture Clinical-Grade NK Cells for Adoptive Immunotherapy

Optimizing the Procedure to Manufacture Clinical-Grade NK Cells for Adoptive Immunotherapy

Natural killer (NK) cells represent promising tools for cancer immunotherapy. We report the optimization of an NK cell activation–expansion process and its validation on clinical-scale. Methods: RPMI-1640, stem cell growth medium (SCGM), NK MACS and TexMACS were used as culture mediums. Activated an...

Full description

Bibliographic Details
Main Authors: Adrián Fernández, Alfonso Navarro-Zapata, Adela Escudero, Nerea Matamala, Beatriz Ruz-Caracuel, Isabel Mirones, Alicia Pernas, Marta Cobo, Gema Casado, Diego Lanzarot, Carlos Rodríguez-Antolín, María Vela, Cristina Ferreras, Carmen Mestre, Aurora Viejo, Alejandra Leivas, Joaquín Martínez, Lucía Fernández, Antonio Pérez-Martínez
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:Cancers
Subjects:
NK cell immunotherapy
NK cell activation and expansion
NKAE cells
clinical-grade manufacturing
CliniMACS Prodigy
Online Access:https://www.mdpi.com/2072-6694/13/3/577

Internet

https://www.mdpi.com/2072-6694/13/3/577

Similar Items